Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 9/2002

01-09-2002 | Leading Article

Potential New Methods for Antiepileptic Drug Delivery

Authors: Dr Robert S. Fisher, Jet Ho

Published in: CNS Drugs | Issue 9/2002

Login to get access

Abstract

Use of novel drug delivery methods could enhance the efficacy and reduce the toxicity of antiepileptic drugs (AEDs). Slow-release oral forms of medication or depot drugs such as skin patches might improve compliance and therefore seizure control. In emergency situations, administration via rectal, nasal or buccal mucosa can deliver the drug more quickly than can oral administration. Slow-release oral forms and rectal forms of AEDs are already approved for use, nasal and buccal administration is currently off-label and skin patches for AEDs are an attractive but currently hypothetical option.
Therapies under development may result in the delivery of AEDs directly to the regions of the brain involved in seizures. Experimental protocols are underway to allow continuous infusion of potent excitatory amino acid antagonists into the CSF. In experiments with animal models of epilepsy, AEDs have been delivered successfully to seizure foci in the brain by programmed infusion pumps, acting in response to computerised EEG seizure detection. Inactive prodrugs can be given systemically and activated at the site of the seizure focus by locally released compounds. One such drug under development is DP-VPA (or DP16), which is cleaved to valproic acid (sodium valproate) by phospholipases at the seizure focus.
Liposomes and nanoparticles are engineered micro-reservoirs of a drug, with attached antibodies or receptor-specific binding agents designed to target the particles to a specific region of the body. Liposomes in theory could deliver a high concentration of an AED to a seizure focus. Penetration of the blood-brain barrier can be accomplished by linking large particles to iron transferrin or biological toxins that can cross the barrier.
In the near future, it is likely that cell transplants that generate neurotransmitters and neuromodulators will accomplish renewable endogenous drug delivery. However, the survival and viability of transplanted cells have yet to be demonstrated in the clinical setting. Gene therapy also may play a role in local drug delivery with the use of adenovirus, adeno-associated virus, herpesvirus or other delivery vectors to induce brain cells to produce local modulatory substances.
New delivery systems should significantly improve the therapeutic/toxic ratio of AEDs.
Footnotes
1
The use of tradenames is for product identification only and does not imply endorsement.
 
Literature
1.
Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39Suppl. 7: S22–6PubMedCrossRef
2.
Johnson MA, Krauss GL, Miller NR, et al. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40–5PubMedCrossRef
3.
Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001; 90: 21–34PubMedCrossRef
4.
5.
Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin Biotechnol 2001; 12: 212–9PubMedCrossRef
6.
Kueltzo LA, Middaugh CR. Potential use of non-classical pathways for the transport of macromolecular drugs. Expert Opin Investig Drugs 2000; 9: 2039–50PubMedCrossRef
7.
Treiman DM, Meyers PD, Walton NY, et al. A comparison of four treatments for generalized convulsive status epilepticus: Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 1998; 339: 792–8PubMedCrossRef
8.
9.
Devinsky O, Leppik I, Willmore LJ, et al. Safety of intravenous valproate. Ann Neurol 1995; 38: 670–4PubMedCrossRef
10.
Wheless JW, Venkataraman V. New formulations of drugs in epilepsy. Expert Opin Pharmacother 1999; 1(1): 49–60PubMedCrossRef
11.
Cardot JM, Degen P, Flesch G, et al. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Dispos 1995; 16: 603–14PubMedCrossRef
12.
Tauboll E, Lindstrom S, Klem W, et al. A new injectable carbamazepine solution: antiepileptic effects and pharmaceutical properties. Epilepsy Res 1990; 7: 59–64PubMedCrossRef
13.
Loscher W, Honack D. Intravenous carbamazepine: comparison of different parenteral formulations in a mouse model of convulsive status epilepticus. Epilepsia 1997; 38: 106–13PubMedCrossRef
14.
Wheless JW. Pediatric use of intravenous and intramuscular phenytoin: lessons learned. J Child Neurol 1998; 13Suppl. 1: S11–4PubMedCrossRef
15.
Stirling LC, Kurowska A, Tookman A. The use of phenobarbitone in the management of agitation and seizures at the end of life. J Pain Symptom Manage 1999; 17: 363–8PubMedCrossRef
16.
Grimshaw D, Holroyd E, Anthony D, et al. Subcutaneous midazolam, diamorphine and hyoscine infusion in palliative care of a child with neurodegenerative disease. Child Care Health Dev 1995; 21: 377–81PubMedCrossRef
17.
Maniatis AK, Klingensmith GJ, Slover RH, et al. Continuous subcutaneous insulin infusion therapy for children and adolescents: an option for routine diabetes care. Pediatrics 2001; 107: 351–6PubMedCrossRef
18.
19.
Asbill CS, El-Kattan AF, Michniak B. Enhancement of transdermal drug delivery: chemical and physical approaches. Crit Rev Ther Drug Carrier Syst 2000; 17: 621–5PubMedCrossRef
20.
Jeannet PY, Roulet E, Maeder-Ingvar M, et al. Home and hospital treatment of acute seizures in children with nasal midazolam. Eur J Paediatr Neurol 1999; 3: 73–7PubMedCrossRef
21.
Khalil S, Philbrook L, Rabb M, et al. Sublingual midazolam premedication in children: a dose response study. Paediatr Anaesth 1998; 8: 461–5PubMedCrossRef
22.
Geldner G, Hubmann M, Knoll R, et al. Comparison between three transmucosal routes of administration of midazolam in children. Paediatr Anaesth 1997; 7: 103–9PubMedCrossRef
23.
Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001; 53: 3–21PubMedCrossRef
24.
Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. Int J Pharm 2001; 212: 29–40PubMedCrossRef
25.
Physicians’ Desk Reference. 55th ed. Montvale (NJ): Medical Economics Company, Ltd., 2001
26.
O’Regan ME, Brown JK, Clarke M. Nasal rather than rectal benzodiazepines in the management of acute childhood seizures? Dev Med Child Neurol 1996; 38: 1037–45PubMedCrossRef
27.
Fisgin T, Gurer Y, Senbil N, et al. Nasal midazolam effects on childhood acute seizures. J Child Neurol 2000; 15: 833–5PubMedCrossRef
28.
Lejus C, Renaudin M, Testa S, et al. Midazolam for premedication in children: nasal vs rectal administration. Eur J Anaesthesiol 1997; 14: 244–9PubMedCrossRef
29.
van Hoogdalem E, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration. Part I: general considerations and clinical applications of centrally acting drugs. Clin Pharmacokinet 1991; 21: 11–26PubMedCrossRef
30.
Dieckmann RA. Rectal diazepam for prehospital pediatric status epilepticus. Ann Emerg Med 1994; 23: 216–24PubMedCrossRef
31.
SneadIII OC, Miles MV. Treatment of status epilepticus in children with rectal sodium valproate. J Pediatr 1985; 106: 323–5PubMedCrossRef
32.
Cereghino JJ, Mitchell WG, Murphy J, et al. Treating repetitive seizures with a rectal diazepam formulation: a randomized study: the North American Diastat Study Group. Neurology 1998; 51: 1274–82PubMedCrossRef
33.
Sharma S, White D, Imondi AR, et al. Development of inhalational agents for oncologic use. J Clin Oncol 2001; 19: 1839–47PubMed
34.
Le Brun PP, de Boer AH, Heijerman HG, et al. A review of the technical aspects of drug nebulization. Pharm World Sci 2000; 22: 75–81PubMedCrossRef
35.
Ganderton D. Targeted delivery of inhaled drugs: current challenges and future goals. J Aerosol Med 1999; 12Suppl. 1: S3–8PubMed
36.
Meeke RI, Soifer BE, Gelb AW. Isoflurane for the management of status epilepticus. DICP 1989; 23: 579–81PubMed
37.
Xi LY, Zheng WM, Zhen SM, et al. Rapid arrest of seizures with an inhalation aerosol containing diazepam. Epilepsia 1994; 35: 356–8PubMedCrossRef
38.
Takeuchi H, Yamamoto H, Kawashima Y. Nasal mucoadhesive drag delivery. Adv Drag Deliv Rev 2001; 47: 39–54CrossRef
39.
Ciordia R, Supko J, Gatineau M, et al. Cytotoxic chemotherapy: advances in delivery, pharmacology, and testing. Curr Oncol Rep 2000; 2: 445–53PubMedCrossRef
40.
Temsamani J, Scherrmann JM, Rees AR, et al. Brain drag technologies: novel approaches for transporting therapeutics. Pharm Sci Technol Today 2000; 3: 155–62PubMedCrossRef
41.
Doolittle ND, Abrey LE, Ferrari N, et al. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the blood-brain barrier disruption consortium. Clin Cancer Res 2002; 8: 1702–9PubMed
42.
Siegal T, Rubinstein R, Bokstein F, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg 2000; 92: 599–605PubMedCrossRef
43.
Orr RM. Technology evaluation: electroporation therapy, Genetronics Inc. Curr Opin Mol Ther 2000; 2: 205–10PubMed
44.
Comford EM. Epilepsy and the blood brain barrier: endothelial cell responses to seizures. Adv Neurol 1999; 79: 845–62
45.
Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drags: a summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res 2001; 43: 11–58PubMedCrossRef
46.
Brightman MW, Kaya M. Permeable endothelium and the interstitial space of brain. Cell Mol Neurobiol 2000; 20: 111–30PubMedCrossRef
47.
Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994; 91: 2076–80PubMedCrossRef
48.
Chen MY, Lonser RR, Morrison PF, et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999; 90: 315–20PubMedCrossRef
49.
Nance P, Meythaler J. Intrathecal drag therapy. Phys Med Rehabil Clin N Am 1999; 10: 385–401PubMed
50.
51.
Meythaler JM, McCary A, Hadley MN. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report. J Neurosurg 1997; 87: 415–9PubMedCrossRef
52.
Munsat TL, Taft J, Jackson IM, et al. Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system. Neurology 1992; 42: 1049–53PubMedCrossRef
53.
Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. Surg Neurol 2001; 55: 79–86PubMedCrossRef
54.
Smith DC, Krahl SE, Browning RA, et al. Rapid cessation of focally induced generalized seizures in rats through microinfusion of lidocaine hydrochloride into the focus. Epilepsia 1993; 34: 43–53PubMedCrossRef
55.
Meldrum B, Millan M, Patel S, et al. Anti-epileptic effects of focal micro-injection of excitatory amino acid antagonists. J Neural Transm 1988; 72: 191–200PubMedCrossRef
56.
Hammarlund-Udenaes M. The use of microdialysis in CNS drag delivery studies: pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drag Deliv Rev 2000; 45: 283–94CrossRef
57.
Eder HG, Jones DB, Fisher RS. Local perfusion of diazepam attenuates interictal and ictal events in the bicuculline model of epilepsy in rats. Epilepsia 1997; 38: 516–21PubMedCrossRef
58.
Eder HG, Stein A, Fisher RS. Interictal and ictal activity in the rat cobalt/pilocarpine model of epilepsy decreased by local perfusion of diazepam. Epilepsy Res 1997; 29: 17–24PubMedCrossRef
59.
Stein AG, Eder HG, Blum DE, et al. An automated drag delivery system for focal epilepsy. Epilepsy Res 2000; 39: 103–14PubMedCrossRef
60.
Osorio I, Frei MG, Wilkinson SB. Real-time automated detection and quantitative analysis of seizures and short-term prediction of clinical onset. Epilepsia 1998; 39: 615–27PubMedCrossRef
61.
Kost J, Langer R. Responsive polymeric delivery systems. Adv Drag Deliv Rev 2001; 46: 125–48CrossRef
62.
63.
Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas: the Polymer-brain Tumor Treatment Group. Lancet 1995; 345: 1008–12PubMedCrossRef
64.
Kokaia M, Aebischer P, Elmer E, et al. Seizure suppression in kindling epilepsy by intracerebral implants of GABA-but not by noradrenaline-releasing polymer matrices. Exp Brain Res 1994; 100: 385–94PubMedCrossRef
65.
Tamargo R, Rossell LA, Tyler BM, et al. Interstitial delivery of diphenylhydantoin in the brain for the treatment of seizures in a rat model. J Neurosurg 1994; 80: 372
66.
Bjorklund A, Lindvall O. Cell replacement therapies for central nervous system disorders. Nat Neurosci 2000; 3: 537–44PubMedCrossRef
67.
Shoichet MS, Winn SR. Cell delivery to the central nervous system. Adv Drug Deliv Rev 2000; 42: 81–102PubMedCrossRef
68.
Tresco PA, Biran R, Noble MD. Cellular transplants as sources for therapeutic agents. Adv Drug Deliv Rev 2000; 42: 3–27PubMedCrossRef
69.
Stafekhina VS, Bragin AG, Vinogradova OS. Integration of hippocampal suspension grafts with host neocortex. Neuroscience 1995; 64: 643–51PubMedCrossRef
70.
Park KI. Transplantation of neural stem cells: cellular & gene therapy for hypoxic-ischemic brain injury. Yonsei Med J 2000; 41: 825–35PubMed
71.
Svendsen CN, Smith AG. New prospects for human stem-cell therapy in the nervous system. Trends Neurosci 1999; 22: 357–64PubMedCrossRef
72.
73.
Buzsaki G, Gage FH. Fetal brain tissue grafts modulate neuronal excitability in a chronic model of epilepsy. Epilepsy Res Suppl 1992; 8: 271–81PubMed
74.
Sloviter R. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the ‘dormant basket cell’ hypothesis and its relevance to temporal lobe epilepsy. Hippocampus 1991; 1: 41–66PubMedCrossRef
75.
Shetty AK, Zaman V, Turner DA. Pattern of long-distance projections from fetal hippocampal field CA3 and CA1 cell grafts in lesioned CA3 of adult hippocampus follows intrinsic character of respective donor cells. Neuroscience 2000; 99: 243–55PubMedCrossRef
76.
Nadler JV. Minireview: kainic acid as a tool for the study of temporal lobe epilepsy. Life Sci 1981; 29: 2031–42PubMedCrossRef
77.
Shetty AK, Turner DA. Fetal hippocampal grafts containing CA3 cells restore host hippocampal glutamate decarboxylase-positive intemeuron numbers in a rat model of temporal lobe epilepsy. J Neurosci 2000; 20: 8788–801PubMed
78.
Loscher W, Ebert U, Lehmann H, et al. Seizure suppression in kindling epilepsy by grafts of fetal GABAergic neurons in rat substantia nigra. J Neurosci Res 1998; 51: 196–209PubMedCrossRef
79.
Brevig T, Holgersson J, Widner H. Xenotransplantation for CNS repair: immunological barriers and strategies to overcome them. Trends Neurosci 2000; 23: 337–4PubMedCrossRef
80.
Schachter SC, Schomer DL, Blume H, et al. Porcine fetal GABA-producing neural cell transplants for human partial-onset seizures: safety and feasibility [abstract]. Epilepsia 1998; 39Suppl. 6:67
81.
82.
Pennacchio LA, Lehesjoki AE, Stone NE, et al. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731–4PubMedCrossRef
83.
84.
Lam PY, Breakefield XO. Potential of gene therapy for brain tumors. Hum Mol Genet 2001; 10: 777–87PubMedCrossRef
85.
Poenaru L. From gene transfer to gene therapy in lysosomal storage diseases affecting the central nervous system. Ann Med 2001; 33: 28–36PubMedCrossRef
86.
Latchman DS, Coffin RS. Viral vectors for gene therapy in Parkinson’s disease. Rev Neurosci 2001; 12: 69–78PubMed
87.
Baekelandt V, De Strooper B, Nuttin B, et al. Gene therapeutic strategies for neurodegenerative diseases. Curr Opin Mol Ther 2000; 2: 540–54PubMed
88.
89.
Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors. Part II: vector systems and applications. Neoplasia 1999; 1: 402–16PubMedCrossRef
90.
Davidson BL, Hilfinger JM, Beer SJ. Extended release of adenovirus from polymer microspheres: potential use in gene therapy for brain tumors. Adv Drug Deliv Rev 1997; 27: 59–66PubMedCrossRef
91.
Bueler H. Adeno-associated viral vectors for gene transfer and gene therapy. Biol Chem 1999; 380: 613–22PubMedCrossRef
92.
Suhr ST, Gage FH. Gene therapy in the central nervous system: the use of recombinant retroviruses. Arch Neurol 1999; 56: 287–92PubMedCrossRef
93.
Kafri T, van Praag H, Gage FH, et al. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1: 516–21PubMedCrossRef
94.
Papadopoulos MC, Giffard RG, Bell BA. Principles of gene therapy: potential applications in the treatment of cerebral ischaemia. Br J Neurosurg 2000; 14: 407–14PubMedCrossRef
95.
Partridge W. Gene targeting technology and gene therapy of the brain. Drug Discov Today 2001; 6: 125–6CrossRef
96.
Yenari MA, Dumas TC, Sapolsky RM, et al. Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors. Neurol Res 2001; 23: 543–52PubMedCrossRef
97.
Hecker JG, Hall LL, Irion VR. Nonviral gene delivery to the lateral ventricles in rat brain: initial evidence for widespread distribution and expression in the central nervous system. Mol Ther 2001; 3: 375–84PubMedCrossRef
98.
Schwartz JJ, Zhang S. Peptide-mediated cellular delivery. Curr Opin Mol Ther 2000; 2: 162–7PubMed
99.
Tabbaa S, Goulah C, Tran RK, et al. Gene transfer into the central nervous system using herpes simplex virus-1 vectors. Folia Morphol (Warsz) 2000; 59: 221–32
100.
Lachmann RH, Efstathiou S. Use of herpes simplex virus type 1 for transgene expression within the nervous system. Clin Sci (Colch) 1999; 96: 533–41CrossRef
101.
Yenari MA, Minami M, Sun GH, et al. Calbindin d28k over-expression protects striatal neurons from transient focal cerebral ischemia. Stroke 2001; 32: 1028–35PubMedCrossRef
102.
Roy M, Horn J, Sapolsky RM. Neuroprotection with herpes simplex vectors expressing virally derived anti-apoptotic agents. Brain Res 2001; 901: 12–22PubMedCrossRef
103.
Dilber MS, Gahrton G. Suicide gene therapy: possible applications in haematopoietic disorders. J Intern Med 2001; 249: 359–67PubMedCrossRef
104.
Fathallah-Shaykh HM, Kafrouni AI, Zhao LJ, et al. Demyelination but no cognitive, motor or behavioral deficits after adenovirus-mediated gene transfer into the brain. Gene Ther 2000; 7: 2094–8PubMedCrossRef
105.
Driesse MJ, Esandi MC, Kros JM, et al. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity. Gene Ther 2000; 7: 1401–9PubMedCrossRef
106.
Kochanek PM, Janesko KL, Jenkins LW, et al. Adenovirus-mediated transfer and expression of beta-gal in injured hippocampus after traumatic brain injury in mice. J Neurotrauma 2001; 18: 73–82PubMedCrossRef
107.
Lundberg C, Jungles SJ, Mulligan RC. Direct delivery of leptin to the hypothalamus using recombinant adeno-associated virus vectors results in increased therapeutic efficacy. Nat Biotechnol 2001; 19: 169–72PubMedCrossRef
108.
Demeneix B, Behr J, Boussif O, et al. Gene transfer with lipospermines and polyethylenimines. Adv Drug Deliv Rev 1998; 30: 85–95PubMedCrossRef
109.
Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv Drug Deliv Rev 2000; 43: 197–205PubMedCrossRef
110.
Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000; 48: 27–38PubMedCrossRef
111.
Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci U S A 2000; 97: 7567–72PubMedCrossRef
112.
Lian T, Ho RJ. Trend and developments in liposome drug delivery systems. J Pharm Sci 2001; 90: 667–80PubMedCrossRef
113.
Drummond DC, Meyer L, Hong K, et al. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743PubMed
114.
Lehtonen JY, Adlercreutz H, Kinnunen PK. Binding of daidzein to liposomes. Biochim Biophys Acta 1996; 1285: 91–100PubMedCrossRef
115.
Yuyama Y, Tsujimoto M, Fujimoto Y, et al. Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. Cancer Lett 2000; 155: 71–7PubMedCrossRef
116.
Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett 1999; 460: 129–33PubMedCrossRef
117.
Yuan F, Dellian M, Fukumura D, et al. Vasuclar permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752–6PubMed
118.
Rubin LL, Staddon JM. The cell biology of the blood brain barrier. Annu Rev Neurosci 1999; 22: 11–28PubMedCrossRef
119.
Bikel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 2001; 46: 247–79CrossRef
120.
Leppla SH, Arora N, Varughese M. Anthrax toxin fusion proteins for intracellular delivery of macromolecules. J Appl Microbiol 1999; 87: 284PubMedCrossRef
121.
Hamm-Alvarez SF. Molecular motors and their role in membrane traffic. Adv Drug Deliv Rev 1998; 29: 229–42PubMedCrossRef
122.
Bengzon J, Brundin P, Kalen P, et al. Host regulation of noradrenaline release from grafts of seizure-suppressant locus coeruleus neurons. Exp Neurol 1991; 111: 49–54PubMedCrossRef
123.
Ferencz I, Kokaia M, Elmer E, et al. Suppression of kindling epileptogenesis in rats by intrahippocampal cholinergic grafts. Eur J Neurosci 1998; 10: 213–20PubMedCrossRef
124.
Clough R, Statnick M, Maring-Smith M, et al. Fetal raphe transplants reduce seizure severity in serotonin-depleted GEPRs. Neuroreport 1996; 8: 341–6PubMedCrossRef
125.
Huber A, Padrun V, Deglon N, et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. Proc Natl Acad Sci U S A 2001; 98: 7611–6PubMedCrossRef
Metadata
Title
Potential New Methods for Antiepileptic Drug Delivery
Authors
Dr Robert S. Fisher
Jet Ho
Publication date
01-09-2002
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 9/2002
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200216090-00001

Other articles of this Issue 9/2002

CNS Drugs 9/2002 Go to the issue

Review Article

New and Emerging Prophylactic Agents for Migraine

Adis Spotlight

Spotlight on Ziprasidone in Schizophrenia and Schizoaffective Disorder

Original Research Article

Nefazodone in the Treatment of Elderly Patients with Depressive Disorders

Review Article

Clinical Implications of CNS Penetration of Antiretroviral Drugs